Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-KRd-PACE in Ultra High-Risk Newly Diagnosed Multiple Myeloma
NCT06140966Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, carfilzomib in multiple myeloma (MM). Started Oct 2023; status: recruiting.
02
Drugs
daratumumabcarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06140966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140966.